 |
59 Diseases |  |
24 Trials |
|
24 Trials |  |
1999 News |  |
| «12...14151617181920212223242526» |
- || lacosamide / generics
THANK YOU @ravimpatelmd @oelkhateeb @souvik_neo for your tireless #pas2019 coverage! With @AmyKKeir & @dralexscrivens these busy academic neonatologists make up the @EBNEo #SoMe team. They DONATE their time & energy to #neoebm dissemination in exchange for NOTHING. THAT is LOVE. (Twitter) - May 7, 2019
- | pregabalin / generics
Clinical, Journal: Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus. (Pubmed Central) - May 7, 2019
We propose a treatment protocol based on a sequential combination of anaesthetics, anti-epileptic drugs and alternative therapies. Strategies to evaluate treatment response and to wean drugs based on clinical results are also proposed.
- || lacosamide / generics
We'll need photos once your #NEC gear arrives, @ravimpatelmd, @mistygoodlab, @crmartin90, & @AmyHairMD! Thank you for recognizing #NECday on May 17! #preventNEC (Twitter) - May 5, 2019
- || lacosamide / generics
Just ordered some cool items for #NECawarenessday May 17th!! Get your swag here 👉🏻 https://t.co/hZFLnythJR @NECsociety @jenncanvasser @ravimpatelmd @AmyHairMD @crmartin90 @mcelroylabiowa @davidhackam @SamirGadepalli @troymarkelmd (Twitter) - May 5, 2019
- | Trileptal (oxcarbazepine) / Novartis
Journal: Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. (Pubmed Central) - Apr 30, 2019
For the older first generation AEDs (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone and valproic acid), much data has accumulated in this regard. However, this is occurring increasingly for the new AEDs (brivaracetam, eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, piracetam, pregabalin, rufinamide, stiripentol, sulthiame, tiagabine, topiramate, vigabatrin and zonisamide).
- | Trileptal (oxcarbazepine) / Novartis
Clinical, Journal: Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Epilepsy Patients of Different Ages. (Pubmed Central) - Apr 30, 2019
In accordance with previous therapeutic drug monitoring studies, our results confirmed that enzyme inducers reduce the LCM trough serum concentrations by 30% to 40%. In children, the effects of comedication are more pronounced but should be confirmed by further studies.
- || lacosamide / generics
Thank you for helping us spread the word, @EBNEO! #preventNEC #NEC2019 #neoEBM @neojae @MineshKhashu @MottDocs @PreemieParentAl @NPAorg @institutopgg @SIGNECconf @SamirGadepalli @jgillferguson @mcelroylabiowa @crmartin90 @ravimpatelmd @AmyHairMD @troymarkelmd @DrGephartRN (Twitter) - Apr 20, 2019
- | lacosamide / generics
Journal: Lacosamide modulates collapsin response mediator protein 2 and inhibits mossy fiber sprouting after kainic acid-induced status epilepticus. (Pubmed Central) - Apr 11, 2019
This study reveals that, in addition to its antiseizure efficacy, LCM has a neuroprotective effect and inhibits the development of epilepsy. CRMP2 is possibly involved in the mechanism by which LCM suppresses MFS and is expected to be a new therapeutic target for treating epileptogenesis.
- | Trileptal (oxcarbazepine) / Novartis
Clinical, Journal, HEOR: Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy. (Pubmed Central) - Apr 11, 2019
CRMP2 is possibly involved in the mechanism by which LCM suppresses MFS and is expected to be a new therapeutic target for treating epileptogenesis. Despite some similar characteristics of newer-generation antiepileptic drugs' effectiveness, levetiracetam stands out with better dynamic improvement of seizure severity and frequency and satisfactory tolerability; typical for pregabalin is a very good dynamic improvement of seizure severity and frequency mainly in patients with focal seizures, but a lower tolerability, and the main advantage of oxcarbazepine is a good tolerability, efficacy, however, is less satisfactory.
- ||| lacosamide / generics
Cadila Healthcare: Gets @US_FDA Tentative Nod For Generic Of Vimpat Tablet (Twitter) - Apr 8, 2019
- | lacosamide / generics
Clinical, Journal: LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting. (Pubmed Central) - Apr 7, 2019
These results of real-life setting show LCM to be efficacious and safe when used as first add-on therapy for focal-onset epilepsy. Most adverse events were mild and/or transient.
- | lacosamide / generics
Preclinical, Journal: Inverted-U response of lacosamide on pilocarpine-induced status epilepticus and oxidative stress in C57BL/6 mice is independent of hippocampal collapsin response mediator protein-2. (Pubmed Central) - Apr 7, 2019
The study reveals that CRMP-2 may not be mediating the inverted-U-response of LCM at least in pilocarpine model. Therefore, the anti-oxidant effect of LCM (and not its ability to modulate CRMP-2) was anticipated as the mechanism underlying neuroprotection.
- | Preclinical, Journal: Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs. (Pubmed Central) - Apr 7, 2019
The different sensitivities of REDs to these ASDs may reflect persistent molecular, cellular, and/or network-level changes resulting from disease. These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy.
- | lacosamide / Generic mfg.
New P2 trial: Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD) (clinicaltrials.gov) - Mar 31, 2019
P2, N=4, Recruiting, Sponsor: University of California, San Francisco
- | lacosamide / generics
Journal: Preparation, Characterization, and Stability Evaluation of Taste-Masking Lacosamide Microparticles. (Pubmed Central) - Mar 29, 2019
Especially the difference in initial dissolution profile observed for LCM-E100 (1:3) indicated rapid reduction in taste-masking effectiveness and surface recrystallization. Therefore, LCM-E100 formulation in the ratio of 1:1 was selected as the best formulation with good taste-masking effectiveness and stability.
- | Retrospective data, Journal: Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. (Pubmed Central) - Mar 29, 2019
In this meta-analysis of >9000 patients, those treated with AEDs were more likely than placebo to achieve seizure response or freedom. Patients receiving pregabalin, tiagabine, and vigabatrin had the highest odds of ≥50% reduction in seizures, and patients receiving ezogabine, levetiracetam, and vigabatrin had the highest odds of seizure freedom.
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
Enrollment open: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Feb 5, 2019
P2, N=232, Recruiting, Sponsor: Duke University
Patients receiving pregabalin, tiagabine, and vigabatrin had the highest odds of ≥50% reduction in seizures, and patients receiving ezogabine, levetiracetam, and vigabatrin had the highest odds of seizure freedom. Not yet recruiting --> Recruiting
- | lacosamide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Lacosamide in Preventing Seizures in Participants With Malignant Glioma (clinicaltrials.gov) - Dec 20, 2018
P=N/A, N=37, Terminated, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=302 --> 37 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Jun 2017
- | lacosamide / Generic mfg.
New P2 trial: The Effect of Lacosamide in Peripheral Neuropathic Pain (clinicaltrials.gov) - Dec 19, 2018
P2, N=108, Not yet recruiting, Sponsor: Danish Pain Research Center
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Nov 8, 2018
P2, N=232, Not yet recruiting, Sponsor: Duke University
N=302 --> 37 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Jun 2017 Trial completion date: Sep 2020 --> Jan 2021 | Initiation date: Aug 2018 --> Dec 2018 | Trial primary completion date: Sep 2020 --> Jan 2021
- | lacosamide / Generic mfg.
Trial completion date: VALOR: A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (clinicaltrials.gov) - Sep 14, 2018
P3, N=250, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial completion date: Sep 2020 --> Jan 2021 | Initiation date: Aug 2018 --> Dec 2018 | Trial primary completion date: Sep 2020 --> Jan 2021 Trial completion date: Jul 2019 --> Mar 2019
- | lacosamide / Generic mfg.
Enrollment change: ASPIRE: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (clinicaltrials.gov) - Sep 14, 2018
P2/3, N=100, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial completion date: Jul 2019 --> Mar 2019 N=75 --> 100
- | New P4 trial: PADRE: Pharmacokinetics of Antiepileptics in Patients on CRRT (clinicaltrials.gov) - Aug 16, 2018
P4, N=30, Recruiting, Sponsor: University of Maryland
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
Enrollment change: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Aug 1, 2018
P2, N=232, Not yet recruiting, Sponsor: Duke University
N=75 --> 100 N=116 --> 232
- | lacosamide / Generic mfg.
New P4 trial: Efficacy and Safety of Rapid Titration Protocols of Lacosamide (clinicaltrials.gov) - Jul 31, 2018
P4, N=75, Not yet recruiting, Sponsor: Seoul National University Hospital
- | lacosamide / Generic mfg.
Enrollment open: Open-label Clinical Trial of Lacosamide in ALS (clinicaltrials.gov) - Jul 18, 2018
P1/2, N=30, Recruiting, Sponsor: Chiba University
N=116 --> 232 Not yet recruiting --> Recruiting
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Drug-induced dermatomyositis after lacosamide: A case report. (Pubmed Central) - Jul 14, 2018
Not yet recruiting --> Recruiting No abstract available
- |||| lacosamide / Generic mfg.
Trial completion date, Trial primary completion date: VALUE: Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures (clinicaltrials.gov) - Jun 11, 2018
P3, N=250, Enrolling by invitation, Sponsor: UCB BIOSCIENCES, Inc.
No abstract available Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
- |||| lacosamide / Generic mfg.
Trial completion: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Apr 25, 2018
P2, N=54, Completed, Sponsor: UCB Pharma
Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jul 2023 --> Jan 2024 Active, not recruiting --> Completed
- | lacosamide / Generic mfg.
Enrollment open: Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers (clinicaltrials.gov) - Apr 9, 2018
P1, N=28, Recruiting, Sponsor: Boston Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| lacosamide / Generic mfg.
Trial completion date, Trial primary completion date: VALOR: A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (clinicaltrials.gov) - Apr 4, 2018
P3, N=200, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Not yet recruiting --> Recruiting Trial completion date: Nov 2018 --> Jul 2019 | Trial primary completion date: Oct 2018 --> May 2019
- |||| lacosamide / Generic mfg.
Trial completion date, Trial primary completion date: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures (clinicaltrials.gov) - Mar 14, 2018
P3, N=500, Enrolling by invitation, Sponsor: UCB BIOSCIENCES, Inc.
Trial completion date: Nov 2018 --> Jul 2019 | Trial primary completion date: Oct 2018 --> May 2019 Trial completion date: May 2021 --> Jun 2022 | Trial primary completion date: Mar 2021 --> Jun 2022
- | lacosamide / Generic mfg.
Trial initiation date: Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers (clinicaltrials.gov) - Mar 3, 2018
P1, N=28, Not yet recruiting, Sponsor: Boston Medical Center
Trial completion date: May 2021 --> Jun 2022 | Trial primary completion date: Mar 2021 --> Jun 2022 Initiation date: Jan 2018 --> Mar 2018
- |||| lacosamide / Generic mfg.
Trial completion date, Trial primary completion date: ASPIRE: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (clinicaltrials.gov) - Mar 3, 2018
P2/3, N=75, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Initiation date: Jan 2018 --> Mar 2018 Trial completion date: Aug 2020 --> Aug 2020 | Trial primary completion date: Aug 2020 --> Aug 2020
- || lacosamide / Generic mfg.
Trial completion date, Trial primary completion date: An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy (clinicaltrials.gov) - Mar 3, 2018
P2, N=300, Enrolling by invitation, Sponsor: UCB Pharma
Trial completion date: Aug 2020 --> Aug 2020 | Trial primary completion date: Aug 2020 --> Aug 2020 Trial completion date: May 2022 --> Jul 2022 | Trial primary completion date: May 2022 --> Jun 2022
- ||||| lacosamide / Generic mfg.
Trial initiation date: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures (clinicaltrials.gov) - Feb 19, 2018
P3, N=500, Enrolling by invitation, Sponsor: UCB BIOSCIENCES, Inc.
Trial completion date: May 2022 --> Jul 2022 | Trial primary completion date: May 2022 --> Jun 2022 Initiation date: Mar 2014 --> Aug 2014
- |||| lacosamide / Generic mfg.
Trial completion date, Trial primary completion date, Monotherapy: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 (clinicaltrials.gov) - Feb 19, 2018
P3, N=150, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Initiation date: Mar 2014 --> Aug 2014 Trial primary completion date: Sep 2018 --> Nov 2019 | Trial completion date: Sep 2018 --> Nov 2019
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
New P2 trial: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Feb 19, 2018
P2, N=116, Not yet recruiting, Sponsor: Duke University
- | lacosamide / Generic mfg.
Trial completion: Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy (clinicaltrials.gov) - Jan 10, 2018
P3, N=25, Completed, Sponsor: Academisch Ziekenhuis Maastricht
Trial primary completion date: Sep 2018 --> Nov 2019 | Trial completion date: Sep 2018 --> Nov 2019 Active, not recruiting --> Completed
- ||| lacosamide / Generic mfg.
Trial completion: VIBES: Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors (clinicaltrials.gov) - Dec 6, 2017
P=N/A, N=93, Completed, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || lacosamide / Generic mfg.
Trial completion, Enrollment change, Monotherapy: A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures (clinicaltrials.gov) - Nov 24, 2017
P3, N=19, Completed, Sponsor: UCB Japan Co. Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 19
- ||| lacosamide / Generic mfg.
Enrollment closed: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Nov 7, 2017
P2, N=54, Active, not recruiting, Sponsor: UCB Pharma
Active, not recruiting --> Completed | N=10 --> 19 Recruiting --> Active, not recruiting
- | Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated, Sponsor: Hannover Medical School
Recruiting --> Active, not recruiting N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
- |||| lacosamide / Generic mfg.
Trial primary completion date: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures (clinicaltrials.gov) - Sep 15, 2017
P3, N=473, Active, not recruiting, Sponsor: UCB Pharma SA
N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017 Trial primary completion date: Sep 2018 --> Jul 2019
- | lacosamide / Generic mfg.
Trial completion: Cognitive and Behavioral Effects of Lacosamide (clinicaltrials.gov) - Sep 14, 2017
P4, N=32, Completed, Sponsor: Evan Fertig
Trial primary completion date: Sep 2018 --> Jul 2019 Recruiting --> Completed
- | lacosamide / Generic mfg.
New P1 trial: Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers (clinicaltrials.gov) - Sep 5, 2017
P1, N=28, Not yet recruiting, Sponsor: Boston Medical Center
- |||| lacosamide / Generic mfg.
Trial primary completion date: VALOR: A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (clinicaltrials.gov) - Sep 1, 2017
P3, N=200, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Completed Trial primary completion date: Jan 2019 --> Oct 2018
- |||| lacosamide / Generic mfg.
Trial primary completion date: VALUE: Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures (clinicaltrials.gov) - Sep 1, 2017
P3, N=200, Enrolling by invitation, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Jan 2019 --> Oct 2018 Trial primary completion date: Dec 2020 --> Jul 2023
- |||| lacosamide / Generic mfg.
Trial primary completion date: Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures (clinicaltrials.gov) - Sep 1, 2017
P3, N=244, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Dec 2020 --> Jul 2023 Trial primary completion date: Jul 2019 --> Aug 2020
- | lacosamide / Generic mfg., ketamine / Generic mfg., levetiracetam / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus (clinicaltrials.gov) - Aug 29, 2017
P3, N=0, Withdrawn, Sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC
Trial primary completion date: Jul 2019 --> Aug 2020 N=40 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Nov 2016